Anti-fibrotic and anti-inflammatory consequences of TGF-β2 silencing in biliary liver disease

Anne Dropmann(University Hospital Heidelberg), NM Meindl-Beinker(Heidelberg University), Diana Jones(RELX Group (Netherlands)), Hanna Korhonen(Heidelberg University), John Brain(Newcastle upon Tyne Hospitals NHS Foundation Trust), Steven Dooley(Heidelberg University), Michel Janicot(Isarna Therapeutics (Germany)), Albrecht Piiper(Goethe University Frankfurt), T. Dediulia(Heidelberg University), Timo Gaiser(University of Mannheim), M. Ebert, Bedair Dewidar(Tanta University)

Zeitschrift für Gastroenterologie

December 19, 2016

10.1055/s-0036-1597348

Cited by 0

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study

|PLoS Medicine|2019|1.1k

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

|Cells|2019|822

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

<scp>TGF</scp>‐β signalling and liver disease

|FEBS Journal|2016|611